Skip to main content
. 2012 Jun 4;30(21):2648–2653. doi: 10.1200/JCO.2011.40.2792

Fig 2.

Fig 2.

Kaplan-Meier curves showing the overall survival (OS) and progression-free survival (PFS) of patients with centrally reviewed metastatic medulloblastoma treated at the recommended phase II dose of carboplatin on regimen A and regimen B. The numbers below the survival curves reflect the number of patients at risk at any given time point.